The AIM All Share dipped by 0.7% to 735.96 in the past five trading days, slightly underperforming the FTSE 100, which remained stagnant during that time.
The AIM All Share dipped by 0.7% to 735.96 in the past five trading days, slightly underperforming the FTSE 100, which remained stagnant during that time.
The acquisition adds scale and diversification to create a stronger global diagnostics business, with a complementary suite of genomic technologies and services
This week AIM All-Share Index, remained relatively unchanged over the week. However, it peaked at 770 on Thursday afternoon, up by half a percentage point from Monday’s opening at 766.
Arrow Exploration (AXL), the operator with a portfolio of assets across key Colombian hydrocarbon basins, provided an update on the operational activity at the Carrizales Norte field on the Tapir
The AIM All-Share Index dropped 1.8% to 740 this week, effectively reflecting the previous week’s poor performance.
RECOMMENDED CASH OFFER by Novacyt UK Holdings Limited (a wholly-owned subsidiary of Novacyt S.A.) for Yourgene Health plc to be effected by means of a Scheme of Arrangement under Part
Novacyt (NCYT) and Yourgene (YGEN) announced that they have reached agreement on the terms and conditions of a recommended cash offer to be made by Novacyt UK, for the entire
Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), a clinical diagnostics company, has announced its audited results for the year ended 31 December 2022.
Paris, France and Eastleigh, UK – 30 January 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the High Court has notified Novacyt
Reading the headlines of strikes of some kind or the other every day this month takes me back 50 years to the early 1970s, which we seem to be repeating
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Bonhill, Coro, Crimson